The nitrogen-containing bisphosphonate, zoledronic acid, increases mineralisation of human bone-derived cells in vitro

Bone

Volumn 34, Issue 1, 2004, Pages 112-123

  Pan, Beiqing ^a   To, Luen Bik ^a   Farrugia, Amanda N ^a   Findlay, David M ^b   Green, Jonathan ^c   Gronthos, Stan ^a   Evdokiou, Andreas ^b   Lynch, Kevin ^d   Atkins, Gerald J ^b   Zannettino, Andrew C W ^a  

^a INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c NOVARTIS PHARMA AG   (Switzerland)

^d AMGEN Australia Pty Ltd   (Australia)

Author keywords

Alkaline Phosphatase; Bisphosphonates; Bone mineralisation; Osteoblast like cells; STRO 1; ZOL; Zoledronic acid

Indexed keywords

ANTIGEN; BISPHOSPHONIC ACID DERIVATIVE; BONE MORPHOGENETIC PROTEIN 2; NITROGEN; OSTEOCALCIN; STRO 1 ANTIGEN; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; BONE CELL; BONE MINERALIZATION; CELL COUNT; CELL DEATH; CELL DIFFERENTIATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOSTASIS; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; EXPERIMENTAL MODEL; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; NUCLEOTIDE SEQUENCE; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; PHENOTYPE; POLYMERASE CHAIN REACTION; QUANTITATIVE ANALYSIS; UPREGULATION;

EID: 9144233505     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2003.08.013     Document Type: Article

References (42)

1. Balena R., Toolan B.C., Shea M., Markatos A., Myers E.R., Lee S.C.et al. The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates. J. Clin. Invest. 92:1993;2577-2586.
2. Berenson J.R., Vescio R., Henick K., Nishikubo C., Rettig M., Swift R.A.et al. A Phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease. Cancer. 91:2001;144-154.
3. Body J.J., Lortholary A., Romieu G., Vigneron A.M., Ford J. A dose-finding study of zoledronate in hypercalcemic cancer patients. J. Bone Miner. Res. 14:1999;1557-1561.
4. Chavassieux P.M., Arlot M.E., Reda C., Wei L., Yates A.J., Meunier P.J. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J. Clin. Invest. 100:1997;1475-1480.
5. Chen T., Berenson J., Vescio R., Swift R., Gilchick A., Goodin S.et al. Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J. Clin. Pharmacol. 42:2002;1228-1236.
6. Coxon F.P., Helfrich M.H., Van't Hof R., Sebti S., Ralston S.H., Hamilton A.et al. Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. J. Bone Miner. Res. 15:2000;1467-1476.
7. D'Aoust P., McCulloch C.A., Tenenbaum H.C., Lekic P.C. Etidronate (HEBP) promotes osteoblast differentiation and wound closure in rat calvaria. Cell Tissue Res. 302:2000;353-363.
8. Derenne S., Amiot M., Barille S., Collette M., Robillard N., Berthaud P.et al. Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment. J. Bone Miner. Res. 14:1999;2048-2056.
9. Ducy P., Zhang R., Geoffroy V., Ridall A.L., Karsenty G. Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell. 89:1997;747-754.
10. Giuliani N., Pedrazzoni M., Negri G., Passeri G., Impicciatore M., Girasole G. Bisphosphonates stimulate formation of osteoblast precursors and mineralized nodules in murine and human bone marrow cultures in vitro and promote early osteoblastogenesis in young and aged mice in vivo. Bone. 22:1998;455-461.
11. Giuliani N., Pedrazzoni M., Passeri G., Girasole G. Bisphosphonates inhibit IL-6 production by human osteoblast-like cells. Scand. J. Rheumatol. 27:1998;38-41.
12. Goziotis A., Sukhu B., Torontali M., Dowhaniuk M., Tenenbaum H.C. Effects of bisphosphonates APD and HEBP on bone metabolism in vitro. Bone. 16:1995;317S-327S.
13. Gronthos S., Zannettino A.C., Graves S.E., Ohta S., Hay S.J., Simmons P.J. Differential cell surface expression of the STRO-1 and alkaline phosphatase antigens on discrete developmental stages in primary cultures of human bone cells. J. Bone Miner. Res. 14:1999;47-56.
14. Hall A. Rho GTPases and the actin cytoskeleton. Science. 279:1998;509-514.
15. Hughes D.E., Wright K.R., Uy H.L., Sasaki A., Yoneda T., Roodman G.D.et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J. Bone Miner. Res. 10:1995;1478-1487.
16. Komori T., Yagi H., Nomura S., Yamaguchi A., Sasaki K., Deguchi K.et al. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell. 89:1997;755-764.
17. Lekic P., Rubbino I., Krasnoshtein F., Cheifetz S., McCulloch C.A., Tenenbaum H. Bisphosphonate modulates proliferation and differentiation of rat periodontal ligament cells during wound healing. Anat. Rec. 247:1997;329-340.
18. Little D.G., Smith N.C., Williams P.R., Briody J.N., Bilston L.E., Smith E.J.et al. Zoledronic acid prevents osteopenia and increases bone strength in a rabbit model of distraction osteogenesis. J. Bone Miner. Res. 18:2003;1300-1307.
19. Luckman S.P., Hughes D.E., Coxon F.P., Graham R., Russell G., Rogers M.J. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J. Bone Miner. Res. 13:1998;581-589.
20. Lyons A.B. Analysing cell division in vivo and in vitro using flow cytometric measurement of CFSE dye dilution. J. Immunol. Methods. 243:2000;147-154.
21. Lyons A.B. Divided we stand: tracking cell proliferation with carboxyfluorescein diacetate succinimidyl ester. Immunol. Cell Biol. 77:1999;509-515.
22. Major P., Lortholary A., Hon J., Abdi E., Mills G., Menssen H.D.et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J. Clin. Oncol. 19:2001;558-567.
23. Masarachia P., Weinreb M., Balena R., Rodan G.A. Comparison of the distribution of 3H-alendronate and 3H-etidronate in rat and mouse bones. Bone. 19:1996;281-290.
24. Mundy G.R. Bone remodeling and its disorders. Metabolic Bone Disease. 1995;Martin Dunitz Ltd. London.
25. Murakami H., Takahashi N., Sasaki T., Udagawa N., Tanaka S., Nakamura I.et al. A possible mechanism of the specific action of bisphosphonates on osteoclasts: tiludronate preferentially affects polarized osteoclasts having ruffled borders. Bone. 17:1995;137-144.
26. Nishikawa M., Akatsu T., Katayama Y., Yasutomo Y., Kado S., Kugal N.et al. Bisphosphonates act on osteoblastic cells and inhibit osteoclast formation in mouse marrow cultures. Bone. 18:1996;9-14.
27. Pataki A., Muller K., Green J.R., Ma Y.F., Li Q.N., Jee W.S. Effects of short-term treatment with the bisphosphonates zoledronate and pamidronate on rat bone: a comparative histomorphometric study on the cancellous bone formed before, during, and after treatment. Anat. Rec. 249:1997;458-468.
28. Ralston S.H., Boyce B.F., Cowan R.A., Fogelman I., Smith M.L., Jenkins A.et al. The effect of 1 alpha-hydroxyvitamin D3 on the mineralization defect in disodium etidronate-treated Paget's disease - A double-blind randomized clinical study. J. Bone Miner. Res. 2:1987;5-12.
29. Reinholz G.G., Getz B., Pederson L., Sanders E.S., Subramaniam M., Ingle J.N.et al. Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts. Cancer Res. 60:2000;6001-6007.
30. Russell R.G., Rogers M.J. Bisphosphonates: from the laboratory to the clinic and back again. Bone. 25:1999;97-106.
31. Sahni M., Guenther H.L., Fleisch H., Collin P., Martin T.J. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J. Clin. Invest. 91:1993;2004-2011.
32. Sato M., Grasser W. Effects of bisphosphonates on isolated rat osteoclasts as examined by reflected light microscopy. J. Bone Miner. Res. 5:1990;31-40.
33. Sato M., Grasser W., Endo N., Akins R., Simmons H., Thompson D.D.et al. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J. Clin. Invest. 88:1991;2095-2105.
34. Stewart K., Walsh S., Screen J., Jefferiss C.M., Chainey J., Jordan G.R.et al. Further characterization of cells expressing STRO-1 in cultures of adult human bone marrow stromal cells. J. Bone Miner. Res. 14:1999;1345-1356.
35. Storm T., Steiniche T., Thamsborg G., Melsen F. Changes in bone histomorphometry after long-term treatment with intermittent, cyclic etidronate for postmenopausal osteoporosis. J. Bone Miner. Res. 8:1993;199-208.
36. Tenenbaum H.C., Torontali M., Sukhu B. Effects of bisphosphonates and inorganic pyrophosphate on osteogenesis in vitro. Bone. 13:1992;249-255.
37. Tsuchimoto M., Azuma Y., Higuchi O., Sugimoto I., Hirata N., Kiyoki M.et al. Alendronate modulates osteogenesis of human osteoblastic cells in vitro. Jpn. J. Pharmacol. 66:1994;25-33.
38. van Beek E.R., Lowik C.W., Papapoulos S.E. Effect of alendronate treatment on the osteoclastogenic potential of bone marrow cells in mice. Bone. 20:1997;335-340.
39. Vitte C., Fleisch H., Guenther H.L. Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption. Endocrinology. 137:1996;2324-2333.
40. Weinstein R.S. Focal mineralization defect during disodium etidronate treatment of calcinosis. Calcif. Tissue Int. 34:1982;224-228.
41. Zerial M., Stenmark H. Rab GTPases in vesicular transport. Curr. Opin. Cell Biol. 5:1993;613-620.
42. Zhao M., Xiao G., Berry J.E., Franceschi R.T., Reddi A., Somerman M.J. Bone morphogenetic protein 2 induces dental follicle cells to differentiate toward a cementoblast/osteoblast phenotype. J. Bone Miner. Res. 17:2002;1441-1451.